Q3 EPS Forecast for ARS Pharmaceuticals Raised by Analyst

Key Points

• Analysts at William Blair have raised their Q3 2025 earnings per share estimate for ARS Pharmaceuticals to ($0.47), an improvement from an earlier forecast of ($0.48).
• ARS Pharmaceuticals reported a Q2 loss of ($0.46) EPS, missing expectations by ($0.05), despite generating revenue of $15.72 million, exceeding analyst estimates.
• Recent insider sales include transactions by CFO Kathleen D. Scott and insider Alexander A. Fitzpatrick, with over 1 million shares sold in the past 90 days, reflecting a significant decrease in their ownership stakes.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Equities researchers at William Blair upped their Q3 2025 earnings per share estimates for shares of ARS Pharmaceuticals in a research note issued to investors on Wednesday, August 13th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings of ($0.47) per share for the quarter, up from their previous estimate of ($0.48). The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share. William Blair also issued estimates for ARS Pharmaceuticals' Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.61) EPS, Q2 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.69) EPS.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.05). ARS Pharmaceuticals had a negative net margin of 42.74% and a negative return on equity of 21.85%. The company had revenue of $15.72 million during the quarter, compared to analyst estimates of $12.92 million.

Separately, Wall Street Zen lowered ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, July 26th. One analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. According to MarketBeat.com, ARS Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $31.00.

ARS Pharmaceuticals Stock Performance

NASDAQ SPRY traded down $1.37 during trading on Monday, reaching $13.50. 3,133,139 shares of the company's stock were exchanged, compared to its average volume of 1,802,729. The company has a debt-to-equity ratio of 0.37, a current ratio of 6.17 and a quick ratio of 5.98. ARS Pharmaceuticals has a fifty-two week low of $10.00 and a fifty-two week high of $18.90. The business has a 50 day moving average price of $16.80 and a 200-day moving average price of $14.35. The stock has a market capitalization of $1.33 billion, a P/E ratio of -27.55 and a beta of 0.90.

Insider Activity

In other ARS Pharmaceuticals news, CFO Kathleen D. Scott sold 12,500 shares of the company's stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $15.00, for a total value of $187,500.00. Following the completion of the transaction, the chief financial officer directly owned 10,042 shares in the company, valued at approximately $150,630. This represents a 55.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Eric Karas sold 15,000 shares of the stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $16.99, for a total value of $254,850.00. Following the completion of the sale, the insider owned 10,315 shares of the company's stock, valued at $175,251.85. The trade was a 59.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 882,649 shares of company stock worth $15,773,760. Company insiders own 33.50% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SPRY. Allspring Global Investments Holdings LLC increased its holdings in ARS Pharmaceuticals by 7.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 368,556 shares of the company's stock worth $4,636,000 after purchasing an additional 24,385 shares in the last quarter. Wells Fargo & Company MN grew its position in ARS Pharmaceuticals by 47.1% in the 4th quarter. Wells Fargo & Company MN now owns 41,701 shares of the company's stock valued at $440,000 after purchasing an additional 13,361 shares during the period. Oppenheimer & Co. Inc. acquired a new stake in ARS Pharmaceuticals in the 1st quarter valued at $189,000. Wealth Enhancement Advisory Services LLC boosted its holdings in ARS Pharmaceuticals by 4.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 60,294 shares of the company's stock worth $636,000 after acquiring an additional 2,670 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its holdings in ARS Pharmaceuticals by 12.9% during the 4th quarter. MetLife Investment Management LLC now owns 33,086 shares of the company's stock worth $349,000 after acquiring an additional 3,769 shares during the last quarter. 68.16% of the stock is owned by institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.